SCHEDULE: Pentwater Capital Divests Entire Verona Pharma Stake

Sentiment:

Beneficial Ownership Report 14 November 2025 4:27 PM

Pentwater Capital Management LP and Matthew Halbower have fully divested their 6.1% stake in Verona Pharma plc.

Worse than expectedThe filing indicates a complete divestment of a significant 6.1% stake by a major institutional investor, Pentwater Capital Management LP, which is generally perceived negatively by the market.

Summary

Pentwater Capital Management LP and Matthew Halbower, collectively referred to as the Reporting Persons, filed a Schedule 13G regarding their beneficial ownership in Verona Pharma plc.
As of September 30, 2025, the Reporting Persons beneficially owned 42,400,000 Ordinary Shares, represented by 5,300,000 American Depositary Shares (ADSs), which constituted 6.1% of Verona Pharma plc's outstanding Ordinary Shares.
Each ADS represents eight Ordinary Shares of Verona Pharma plc.
As of the filing date, November 14, 2025, the Reporting Persons' aggregate beneficial ownership in Verona Pharma plc is 0%, indicating a complete divestment of their prior stake.
The percentage of class was calculated based on 691,966,902 Ordinary Shares outstanding as of August 11, 2025, as reported in the Company's Definitive Proxy Statement on Schedule 14A filed August 18, 2025.

Sentiment

Score: 3

Explanation: The filing indicates a complete divestment of a significant 6.1% stake by a major institutional investor, which is generally perceived negatively by the market, suggesting a lack of confidence or a change in investment strategy.

Negatives

The complete divestment of a 6.1% beneficial ownership stake by a significant institutional investor like Pentwater Capital Management LP could be interpreted as a negative signal regarding the company's future prospects or the investor's confidence.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders may react negatively to the news of a significant institutional divestment, potentially leading to downward pressure on the stock price due to perceived loss of institutional confidence.

Key Dates

Date	Description
08/11/2025	Date used for calculating outstanding Ordinary Shares (691,966,902 shares).
08/18/2025	Date Verona Pharma plc's Definitive Proxy Statement on Schedule 14A was filed with the SEC.
09/30/2025	Date of event which required the filing, when Reporting Persons beneficially owned 6.1% of outstanding Ordinary Shares.
11/14/2025	Date of filing of this Schedule 13G statement.

Recommendation

sell

The filing reveals that Pentwater Capital Management LP and Matthew Halbower, who previously held a 6.1% beneficial ownership in Verona Pharma plc as of September 30, 2025, have since divested their entire stake, resulting in 0% ownership as of the filing date. Such a complete divestment by a significant institutional investor typically signals a lack of confidence or a change in investment strategy, which could exert downward pressure on the stock price. Therefore, a 'sell' recommendation is warranted based on this institutional exit.

Keywords

Verona Pharma, VRNA, Pentwater Capital Management, Matthew Halbower, Schedule 13G, Beneficial Ownership, Divestment, ADSs, Ordinary Shares

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.